14th February, 2025
Launches novel FDA-cleared AI-powered products for early disease detection.
Prenuvo, the leader in proactive whole-body MRI screening, disclosed that it quietly raised $120M as part of Series B fundraising during 2024, demonstrating its category leadership in preventative health. The company has identified over 1.4 million personalized health insights across its member base, highlighting the critical role of early detection. This milestone comes as Prenuvo surpassed 110,000 members and secured FDA clearance for its AI-powered Prenuvo Body Composition report.
“Prenuvo is leading a movement to make proactive healthcare accessible and transformative for everyone,” said Andrew Lacy, CEO of Prenuvo Inc. “We’re introducing a new approach to early detection that empowers individuals to take control of their health before symptoms emerge. This isn’t just about healthcare; it’s about reimagining how we approach health, using cutting-edge technology and world-class expertise to prevent disease and help people live longer, healthier lives.”
The round, co-led by Forerunner Ventures, Left Lane Capital, and existing investor Felicis, has accelerated Prenuvo’s augmentation of its core industry-leading whole-body MRI screening with additional modalities and analyses of the human body.
Innovative Product Expansion
Prenuvo announced FDA clearance for its AI-powered Prenuvo Body Composition report, marking a significant milestone in the company’s growth. Building on this momentum, Prenuvo introduces three major advances:
These new capabilities will launch immediately in a bundled offering called Prenuvo Enhanced in Silicon Valley, Los Angeles and New York locations, with other locations offering these enhanced screenings in the spring.
“Last year demonstrated an unmistakable shift in consumer behavior towards proactive health management,” said Sundeep Peechu, Managing Partner at Felicis. “Prenuvo has a unique integrated model that is difficult to replicate, and their advanced screening positions them to lead this transformation in preventative healthcare.”
Deliberate Growth and Clinical Excellence
Prenuvo has built the world’s largest private radiology group focused solely on whole-body MRI, with over 80 board-certified radiologists. This expertise has driven research collaborations with premier academic centers studying health, aging, and disease through the unique combination of MRI and AI.
Unlike others who outsource both imaging and radiology services, Prenuvo is fully vertically integrated, owning and operating 17 dedicated centers across North America. With a growing movement to prioritize preventative healthcare, Prenuvo will bring its revolutionary approach to 15 more clinics, including Europe and Australia, marking its first international expansion outside of North America.
“With only 2.5% of healthcare spending focused on preventative medicine, the US system waits for people to become sick before intervening,” said Brian O’Malley from Forerunner. “Consumers have grown tired of this and are responding with their own wallets. Prenuvo is the preeminent solution for a comprehensive understanding of one’s health, giving today’s patients unprecedented levels of knowledge to not just understand, but proactively intervene in the challenges that arise as we all age. Longevity is the new luxury and Prenuvo is democratizing access so that more can benefit from this.”
“Prenuvo has empowered patients in ways that conventional medical care simply hasn’t. Consumers are taking ownership and seeking answers outside of the traditional healthcare system. The physician and clinical ecosystem is waking up to the needs and wants of their patients, who are increasingly demanding proactive and preventative healthcare solutions like Prenuvo,” says Harley Miller, Managing Partner & CEO, Left Lane Capital. “We look forward to seeing how the team continues to scale, advance their proprietary research, and build on their life-changing (and saving) technology.”
Medtech Special
Artificial Intelligence Breakthroughs
Robots In Medtech
© 2023 MM Activ Sci-Tech Communications. All rights reserved | Disclaimer